Drug Pipeline News

A look back at the FDA approvals, label expansions, and regulatory decisions in the pediatric health care space from April through June 2026.

A preview of 5 pending FDA decisions for pediatric patients expected in the second half of 2026, spanning ADHD, psoriasis, a metabolic gene therapy, cardiomyopathy, and muscular dystrophy.

BM-3103 received FDA Fast Track designation for epidermolysis bullosa simplex as a phase 2 trial evaluates safety and efficacy.

Teva's NDA for ecopipam rests on phase 3 data showing a 50% relapse-risk cut, potentially the first new pediatric Tourette mechanism in a decade.

FDA approved the first generic rifapentine for active and latent tuberculosis, expanding treatment options for eligible pediatric patients.

In a parallel regulatory action, the European Medicines Agency has also validated a marketing application for Tivicay covering the neonatal indication.

New FDA-approved options for molluscum contagiosum—in-office cantharidin and at-home berdazimer gel—reduce stigma and avoid painful removal.

Cadrenal has announced that it plans to seek FDA Rare Pediatric Disease Designation for tecarfarin in children with Kawasaki disease and coronary aneurysms.

Baloxavir marboxil is a first-in-class cap-dependent endonuclease inhibitor that functions as a prodrug.

The approval is based on data from the phase 3 STRIDE-13 trial.

BioMarin reports 3-year vosoritide growth data in hypochondroplasia and early BMN 333 findings in achondroplasia.

pCPA gains FDA Orphan Drug Designation for monoamine oxidase deficiency, signaling early development for an ultrarare neurodevelopmental disorder.

Diazoxide choline showed sustained hyperphagia improvements in Prader-Willi syndrome after randomized withdrawal and retreatment.

Setmelanotide reduced BMI measures, fat mass, and hyperphagia scores in interim phase 2 Prader-Willi syndrome data.

The FDA has approved gadoquatrane (Ambelvist), a next-generation macrocyclic GBCA that delivers effective CNS and whole-body MRI contrast at 60% less gadolinium than standard macrocyclic agents.

The FDA granted accelerated approval to teplizumab (Tzield) for children aged 8–17 with recently diagnosed stage 3 T1D, based on PROTECT phase 3 data.

The integrated CGM, first cleared over-the-counter for adults in 2024, is now available without a prescription for people 2 years of age and older who do not use insulin.

New ADA 2026 analyses show Afrezza delivered comparable glycemic control, favorable safety, and higher treatment satisfaction in youth.

The FDA has approved expanded indications for tocilizumab-bavi (TOFIDENCE), adding severe or life-threatening CAR T-cell–induced CRS and hospitalized COVID-19 in patients aged 2 years and older.

The FDA has accepted Takeda's supplemental application for IV vedolizumab in patients ages 2 and older with moderate-to-severe UC or Crohn's disease, with a PDUFA date set for Q1 2027.

The FDA has approved an every-8-week maintenance regimen for lebrikizumab-lbkz (EBGLYSS), giving eligible adults and adolescents with moderate-to-severe atopic dermatitis as few as 6 injections per year without mandatory topical therapy.

The FDA has approved bemotrizinol as the first new active sunscreen ingredient under the OTC monograph in nearly two decades, clearing the broad-spectrum UV filter for use in adults and children 6 months of age and older.

FDA designations for investigational GEn-1123 may support development in Duchenne muscular dystrophy, but clinical data remain limited.

Vertex reported phase 3 ALYFTREK data in children aged 2 to 5 years with cystic fibrosis and responsive CFTR genotypes.

The FDA has broadened the approved indication for marstacimab (Hympavzi; Pfizer) to include pediatric patients ages 6–11 with hemophilia A or B and patients 12 and older with inhibitors.